SR58611A

Phase 3Small molecule

Sanofi

SR58611A is one of 77 small molecule programs targeting Major Depressive Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Major Depressive DisorderActive, not recruiting

Generalized Anxiety DisorderActive, not recruiting

Major Depressive DisorderPhase 3

Active, not recruiting

Generalized Anxiety DisorderPhase 3

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Elavil

AstraZeneca

Phase 3

2 2

Nuplazid

AACADIA Pharmaceuticals Inc.

Phase 3

4 3

Bupropion XL

GSK

Phase 3

1 4

SPD489

Takeda

Phase 3

3 5

Venlafaxine ER

Pfizer

Phase 3

2 6

MK0869, Aprepitant

Merck & Co.

Phase 3

4 7

Antidepressant Therapy

AbbVie

Phase 3

4 8

Saredutant

Sanofi

Phase 3

3 9

Vraylar

SR58611A

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Generalized Anxiety Disorder5 trials

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder

Completed· Sanofi logo

Sanofi·Phase 3·NCT00332891·508 enrolled

Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00397098·257 enrolled

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Generalized Anxiety Disorder

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00535340·55 enrolled

Show 2 more trials

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder

Completed· Sanofi logo

Sanofi·Phase 3·NCT00266747·366 enrolled

Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder

Completed· Sanofi logo

Sanofi·Phase 3·NCT00252343·360 enrolled

Major Depressive Disorder4 trials

A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder

Completed· Sanofi logo

Sanofi·Phase 3·NCT00345098·704 enrolled

Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder

Completed· Sanofi logo

Sanofi·Phase 3·NCT00432614·510 enrolled

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder

Completed· Sanofi logo

Sanofi·Phase 3·NCT00252356·468 enrolled

Show 1 more trial

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder

Completed· Sanofi logo

Sanofi·Phase 3·NCT00252330·476 enrolled

Efficacy and Safety1 trial

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression

Completed· Sanofi logo

Sanofi·Phase 3·NCT00319709·288 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for SR58611A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SR58611A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SR58611A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

SR58611A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Generalized Anxiety Disorder5 trials

Major Depressive Disorder4 trials

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News